Ikena Oncology

Site - Secondary

  • Contact
  • LinkedIn
  • Twitter

Site - Top

  • About
    • Our Company
    • Leadership
    • Partners
    • Contact
  • Focus
    • Our Approach
    • Publications
  • Pipeline
    • Development Pipeline
    • IK-930 TEAD Inhibitor
    • IK-007 EP4 Antagonist
    • IK-175 AHR Antagonist
    • IK-412 Kynase Program
  • Careers
    • Culture
    • Job Opportunities
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financial Filings
    • Corporate Governance
    • Investor Resources
  • Site - Top

    • About
      • Our Company
      • Leadership
      • Partners
      • Contact
    • Focus
      • Our Approach
      • Publications
    • Pipeline
      • Development Pipeline
      • IK-930 TEAD Inhibitor
      • IK-007 EP4 Antagonist
      • IK-175 AHR Antagonist
      • IK-412 Kynase Program
    • Careers
      • Culture
      • Job Opportunities
    • Investors & Media
      • Corporate Profile
      • Press Releases
      • Events & Presentations
      • Stock Information
      • Financial Filings
      • Corporate Governance
      • Investor Resources
    • Contact
    • Privacy Policy
    • Terms of Use
    • LinkedIn
    • Twitter

SEC Filings

Filing date Form Description View
Apr 15, 2021 SC 13D

Filing by person(s) reporting owned shares of common stock in a public company >5%

0000947871-21-000427.pdf
0000947871-21-000427.rtf
0000947871-21-000427.xls
View HTML
Apr 15, 2021 8-K

Report of unscheduled material events or corporate event

0001193125-21-117138.pdf
0001193125-21-117138.rtf
0001193125-21-117138.xls
View HTML
Apr 15, 2021 3

Initial filing by director officer or owner of more than ten percent.

0000899243-21-015995.pdf
0000899243-21-015995.rtf
0000899243-21-015995.xls
View HTML
Apr 15, 2021 4

Statement of changes in beneficial ownership of securities

0000899243-21-016001.pdf
0000899243-21-016001.rtf
0000899243-21-016001.xls
View HTML
Apr 14, 2021 4/A

Amendment to a previously filed 4

0000947871-21-000426.pdf
0000947871-21-000426.rtf
0000947871-21-000426.xls
View HTML
Apr 13, 2021 4/A

Amendment to a previously filed 4

0000947871-21-000420.pdf
0000947871-21-000420.rtf
0000947871-21-000420.xls
View HTML
Apr 12, 2021 SC 13G

A statement of beneficial ownership of common stock by certain persons

0000315066-21-001500.pdf
0000315066-21-001500.rtf
View HTML
Apr 09, 2021 SC 13G

A statement of beneficial ownership of common stock by certain persons

0001104659-21-048782.pdf
0001104659-21-048782.rtf
0001104659-21-048782.xls
View HTML
Apr 05, 2021 SC 13G

A statement of beneficial ownership of common stock by certain persons

0000921895-21-000937.pdf
0000921895-21-000937.rtf
0000921895-21-000937.xls
View HTML
Apr 05, 2021 SC 13G

A statement of beneficial ownership of common stock by certain persons

0001140361-21-011655.pdf
0001140361-21-011655.rtf
0001140361-21-011655.xls
View HTML

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Next page Next ›
  • Last page Last »

Data provided by Kaleidoscope.

Site - Side

  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
  • Financial Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
  • Investor Resources
    • Investor FAQs
    • Investor Email Alerts
    • Contact IR

Investors & Media Contact

  • Argot Partners
  • (212) 600-1902
  • ikena@argotpartners.com

Tools

  • Print Page
  • Email Alerts
  • RSS Feeds
Footer Logo
Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210
  • Privacy Policy
  • Terms of Use
Footer Logo
Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210
  • About
  • Our Company
  • Leadership
  • Partners
  • Contact
  • Focus
  • Our Approach
  • Publications
  • Pipeline
  • Development Pipeline
  • IK-930 TEAD Inhibitor
  • RAS Signaling Program
  • IK-007 EP4 Antagonist
  • IK-175 AHR Antagonist
  • IK-412 Kynase Program
  • Careers
  • Culture
  • Job Opportunities
  • Investors & Media
  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
  • Financials & Filings
  • Corporate Governance
  • Investor Resources
  • Privacy Policy
  • Terms of Use
  • LinkedIn
  • Twitter
© 2021 Ikena Oncology™